- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04025125
Pathways to Cardiovascular Disease Prevention (DCRI Central and Statistical Coordinating Center)
Pathways to Cardiovascular Disease Prevention and Impact of Specialty Referral in Underrepresented Racial/Ethnic Minorities With HIV (Coordinating Center)
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Aim 1. To identify factors associated with cardiology referral in under-represented racial and ethnic minority (URM) populations with HIV and elevated cardiovascular risk Aim 2. To evaluate the association between cardiology referral and CVD outcomes in under-represented racial and ethnic populations with HIV and elevated cardiovascular risk Sub-Aim 2a. To evaluate the association between cardiology referral and guideline-based CVD prevention measures in URM populations with HIV and elevated CVD risk
Note: Aims 1 and 2-retrospective analysis with anticipated 8000 EHR records to be reviewed.
Aim 3. To identify facilitators and barriers to optimal CVD prevention
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27707
- Duke University
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- University Hospitals Cleveland Medical Center
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37232-2582
- Vanderbilt University Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Aims 1 and 2 not recruiting patients
Aims 3 population of interest:
- Race equals Black/African-American, American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander, or More than one race, and/or Ethnicity equals Hispanic or Latino;
- Documented evidence of HIV positive status (HIV positive diagnosis and prescription of antiretroviral therapy (ART));
Beschreibung
Aims 1 and 2 are not recruiting as retrospective review of electronic health records.
Aims 1 and 2 Inclusion Criteria:
Patient health records may be accessed from subjects who meet the following criteria:
- Race equals Black/African-American, American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander, or More than one race, and/or Ethnicity equals Hispanic or Latino;
- Documented evidence of HIV positive status (HIV positive diagnosis (ICD10 codes B20-B24, or ICD9 codes 042, V08) and prescription of antiretroviral therapy (ART));
- Documented evidence of elevated AtheroSclerotic CardioVascular Disease risk (ACC/AHA ASCVD 10 year risk ≥5%24, or Framingham Cardiovascular Disease 10 year risk ≥5%25) after HIV diagnosis. The date when the patient first meets either of these CVD risk thresholds and with 1 prior encounter not having CVD risk score defines the index time-point for Aim 1 of this study. These risk calculations depend on sex, age, body mass index, diabetes, current smoking, total cholesterol, HDL cholesterol, systolic blood pressure, and treatment for hypertension (defined from diagnosis codes). If cholesterol measures are not available, then body mass index may be used in place of lipids in the Framingham risk calculation; NOTE: must have a prior encounter within 365 days within health system prior to index
- Presence of a modifiable risk factor: hypertension, diabetes, elevated total cholesterol, elevated LDL cholesterol and/or tobacco use.
Aims 1 and 2 Exclusion criteria:
- Age <18 years of age or >99 years of age at index event;
- Pre-existing ASCVD prior to index event, including a previous diagnosis of any acute myocardial infarction, heart failure, acute coronary syndromes, stable or unstable angina, arterial revascularization (includes coronary arterial or peripheral), stroke, transient ischemic attack or peripheral arterial disease presumed to be of atherosclerotic origin determined by ICD codes;
- Encounter with cardiology specialist within 1 year prior to index
- Evidence of ART for pre-exposure prophylaxis (i.e., Truvada [emtricitabine/tenofovir disoproxil fumarate] or post-exposure prophylaxis (e.g., Truvada plus raltegravir) without HIV diagnosis.
Aim 3 Inclusion Criteria:
Patients:
- under-represented racial and ethnic minority (URM) populations with HIV > 40 years of age, with
- a modifiable risk factor for Cardiovascular disease (CVD) (such as hypertension, diabetes, elevated total cholesterol, high LDL cholesterol, or currently use tobacco), and/or known CVD
Providers
- HIV providers will include infectious disease physicians, Internists or advance practice practitioners who report having seen > 1 person living with HIV under their care in the last 6 months; AND
- Cardiology providers (physicians or advance practice providers) will be required to have taken care of at least 1 HIV-positive patient in the past 3 years;
Aim 3 Exclusion Criteria:
Patients
- Unwilling or unable to provide oral informed consent;
- Unable to perform an interview in English;
- Diminished capacity to give oral consent;
- Unwilling to be interviewed.
Providers
- Unable to perform an interview in English;
- Unwilling to be interviewed.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Proportion of patients with referral to a cardiology specialist (primary outcome for Aim 1)
Zeitfenster: 6 months from the date when patient met eligibility criteria for referral
|
A binary variable, with 'yes' defined if there is documented evidence that a referral is made within 6 months of becoming eligible by CVD risk score and kept within 3 months of referral, and 'no' otherwise.
Cardiology referrals with kept appointments will be ascertained from electronic health record data.
|
6 months from the date when patient met eligibility criteria for referral
|
Proportion of patients with blood pressure control (primary outcome for Aim 2)
Zeitfenster: Longitudinal evaluation during 5 years of follow up.
|
Blood pressure control will be defined based on prevailing guidelines during the study period (blood pressure <140/90 mmHg) and will be evaluated based on blood pressures recorded in electronic health record data.
|
Longitudinal evaluation during 5 years of follow up.
|
Proportion of patients with Cholesterol control (co-primary outcome for Aim 2)
Zeitfenster: Longitudinal evaluation during 5 years of follow up.
|
Cholesterol control will be defined based on prevailing guidelines during the study period and will be evaluated based on cholesterol laboratory measures recorded in electronic health record data.
|
Longitudinal evaluation during 5 years of follow up.
|
Patient perspective on facilitators and barriers to optimal CVD prevention (co-primary outcome for Aim 3)
Zeitfenster: Approximately 60 minutes
|
Qualitative information will be assessed from semi-structured interviews conducted with participating patients
|
Approximately 60 minutes
|
Provider perspective on facilitators and barriers to optimal CVD prevention (co-primary outcome for Aim 3)
Zeitfenster: Approximately 60 minutes
|
Qualitative information will be assessed from semi-structured interviews conducted with participating healthcare providers
|
Approximately 60 minutes
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Incidence of major adverse cardiovascular event, myocardial infarction (secondary outcome for Aim 2)
Zeitfenster: 5 years
|
Incidence of first major adverse cardiovascular event (composite of cardiovascular death and myocardial infarction) will be determined from diagnosis and/or procedure codes from electronic health record data and a query of the National Death Index (Plus).
|
5 years
|
Incidence of Stroke (secondary outcome for Aim 2)
Zeitfenster: 5 years
|
Incidence of first stroke event will be determined from diagnosis and/or procedure codes from electronic health record data.
|
5 years
|
Incidence of All-cause death (secondary outcome for Aim 2)
Zeitfenster: 5 years
|
Incidence of all-cause death will be determined from electronic health record data and a query of the National Death Index.
|
5 years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Gerald Bloomfield, MD, Duke Health
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- Pro00101104
- 1R01MD013493-01 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .